Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractVaccination remains the most valuable tool for preventing infectious diseases. However, the performance of many existing vaccines should be improved and there are diseases for which vaccines are still not available. The use of well-defined antigens for the generation of subunit vaccines has led to products with an improved safety profile. However, purified antigens are usually poorly immunogenic, making essential the use of adjuvants. Despite the fact that adjuvants have been used to increase the immunogenicity of vaccines for more than 70 years, only a handful has been licensed for human use (e.g., aluminium salts, the micro-fluidized squalene-in-water emulsion MF59 and monophosphoryl lipid A). Thus, the development of new adjuvants which are able to promote broad and sustained immune responses at systemic and mucosal levels still remains as a major challenge in vaccinology. Recent advances in our understanding of the immune system have facilitated the identification of new biological targets for screening programs aimed at the discovery of novel immune stimulators. This resulted in the identification of new candidate adjuvants, which made possible the modulation of the immune responses elicited according to specific needs. A number of promising adjuvants which are currently under preclinical or clinical development will be described in this review.
CitationImmune modulators with defined molecular targets: cornerstone to optimize rational vaccine design., 4 (1):13-22 Hum Vaccin
AffiliationDepartment of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
The following license files are associated with this item:
- Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design.
- Authors: Ebensen T, Guzmán CA
- Issue date: 2009
- New adjuvants for parenteral and mucosal vaccines.
- Authors: Guy B, Burdin N
- Issue date: 2005 May-Jun
- Mucosal delivery of vaccine antigens and its advantages in pediatrics.
- Authors: De Magistris MT
- Issue date: 2006 Apr 20
- Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.
- Authors: Del Giudice G, Rappuoli R, Didierlaurent AM
- Issue date: 2018 Oct
- Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.
- Authors: Wang X, Meng D
- Issue date: 2015 Mar